Change in Primary Outcomes Over Time in the Mirabegron and Placebo Groups
A and B, Treatment-specific changes in left ventricular mass index (A) and E/e′ ratio (B) at postbaseline visits, deduced from the basic linear mixed model. Because the groups were randomized, the mean at baseline was not estimated separately by group. 